Today, Jan. 28., 2019, “FDA approved the use of IMBRUVICA® (ibrutinib) in combination with obinutuzumab (GAZYVA®) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The latest FDA approval expands the use of IMBRUVICA, which can already be administered as a single agent or in combination with bendamustine and rituximab (BR) for adult CLL/SLL patients”
For the full press release, click here (https://www.pharmacyclics.com/press-room/press-article?article=118aae51-e18e-61a6-ac91-ff01003424c7)
This is good news as this means that these two very powerful drugs can now be used together “on label” making it easier to get insurance to pay for this potent combination. And even more exciting is the possibility with the combination of getting to where to where there is no detectable disease (U-MRD or undetectable- minimal residual disease) and both drugs can be stopped. Very positive development!